MENA emerging as trial destination says ClinTec CEO

By Gareth Macdonald

- Last updated on GMT

Related tags: Middle east

Improving healthcare infrastructure across the region and a large treatment-naïve patient population makes the Middle East and North Africa (MENA) an increasingly attractive destination for drug trials says ClinTec CEO Rabinder Buttar.

Dr Buttar, who spoke with Outsoucing-pharma a few days after ClinTec reported a 45 per cent hike in 2009 sales, said that while the MENA trials sector is small on a global scale, the region has all the right elements for considerable growth.

She cited the growing number of new high-tech hospitals, the highly educated medical workforce and the increased presence of global regulators among MENA’s attractive features for trial sponsors.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars